SCYNEXISSCYX
Recorded

SCYNEXIS 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration25 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Vamil DivanManaging Director

Innovation Conference. I'm Vamil Divan, one of the biopharm analysts here at Guggenheim. Pleased to join us now next in this room, we have the team from SCYNEXIS, David Angulo up here, the CEO of the company. We do have a few slides we're going to kind of show throughout the course of the discussion. David, maybe I'll just have you start by just, for people less familiar with SCYNEXIS and the story, a little bit of an overview. It's been a sort of transformative year for you, so where things stand now, and then we'll look forward from there.

David AnguloCEO

Thank you. Thank you for the invitation, Vamil and SIA. Certainly, to tell you a little bit about the company, the ones that you are not familiar with. We're focusing really advancing innovative solutions for rare disease spaces. What you, Vamil, mentioned about really the developments over the past year, what we did is that in the past, we were focusing development of antifungal products for many years. We have a long platform of antifungal products that we were developing in invasive fungal disease infections. We recently acquired an asset that we are developing in the ADPKD space. Primary reason for really expanding our indications into the ADPKD space was obviously, this is an area, it's still in the rare disease space that we were quite interested on, has an area of significant attractive market, a lot of development opportunities.

David AnguloCEO

It's an area that is substantially underserved by current therapeutic options, and obviously was a way to really provide a potential shareholder value creation opportunity within the space. At this point, really, we have evolved the company right now in having two programs, one in ADPKD and one in invasive fungal disease infections. We have already developed a product in the past that we partnered with GSK, which is called BREXAFEMME. At this point, it's fully out-licensed to them, for which we are eligible to receive some sales milestones about it.

Vamil DivanManaging Director

Okay, great. Maybe we can talk more about SCY-770 and the potential there in ADPKD. Just maybe you can give a little more background on the product itself, this mechanism, and why you think this has a potential in ADPKD.

David AnguloCEO

Yeah, thank you. Yes, we selected this particular product for acquisition really because we were very much attracted by the mechanism of action in this particular disease. I don't know if you're familiar, but in the ADPKD space, there is only one therapeutic alternative right now, that it is, I would say, not very much used because the fact that it has a very significant safety connotations and lack of tolerability. Beside of that, it's a very substantial market opportunity. This particular product that we're licensing has a novel mechanism of action that is very well validated by the scientific community to have the opportunity to really deliver a clinically meaningful effect in ADPKD patients. It's a product that has already been administered in around 300 individuals in different stages of clinical trials.

David AnguloCEO

It's ready for really initiation of phase II that we're planning to initiate by the end of this year, and really has a very clear path for regulatory approval. It has a good IP protection. Those were kind of elements that really drove too much into our decision to really bring this product into the company. More specifically, addressing your question regarding the mechanism of action. ADPKD is a disease that it is generated by the mutation of one or two genes that are responsible for the production of certain proteins, polycystin-1 proteins, that are needed or essential for the adequate functioning of the tubular epithelial cells. When these two proteins are not present, there is a cascade of events in which they start really forming cysts, and those cysts start taking over the entire kidney architecture, and they ended up causing kidney dysfunction.

David AnguloCEO

It is well-known that AMPK activation is reduced during this physiopathological pathway, and by reactivating this enzyme that is responsible for multiple metabolic aspects in the cells, by reactivating this enzyme via a direct AMPK activator, we are able to modify critical pathways like the mTOR, cyclic AMP, that are responsible for the cyst proliferation. We are also able to really reduce the fluid secretion into the cells by the chloride channels, and also reduce inflammation, which I would say that three of the key hallmarks of this particular disease. What we are also very excited about this AMPK activator is that it has a very high selectivity. So it binds preferentially into the versions of this enzyme that are more common in the kidney space, rather than binding into other versions of that enzyme that may be more common in other type of organs.

David AnguloCEO

With that type of selectivity, really allows you to have a better safety profile.

Vamil DivanManaging Director

Okay, great. You did have some phase I data, I think, that you've shared also. Maybe you can review that.

David AnguloCEO

That's right. We actually conducted a phase I study in order to evaluate additional doses that had not been evaluated with this particular molecule in the past. We recently announced the completion of that particular study, and with that data from that study, the doses that we evaluated were higher than doses previously evaluated, had allowed us to really conduct a population PK modeling in order to inform us properly about the doses that we are proposing for the phase II study that we are planning to initiate by the end of this year. The positive data is that all those doses were well tolerated. We were able to further characterize the pharmacokinetic profile of those doses. We're in the process of discussing with the FDA our final study design for phase II and really trying to move it into initiation towards the end of the year.

Vamil DivanManaging Director

Okay. Great. I know you're still in discussions and finalizing, but maybe you can give us a sense of what you're hoping or what you're expecting to show in terms of the design for the phase II program.

David AnguloCEO

Yeah. The outline of the design for the specifics of the design, as I mentioned to you, we'll probably share them once we do have a reached agreement with the agency. But the outline is a full one-year treatment period. We're aiming to really have three groups of patients, two of them receiving two different doses of SCY-770, and one receiving placebo. It's going to be a full year treatment duration. We are aiming to have an interim readout towards the end of next year, and that particular interim readout will give us an indication of the progression or the impact in the progression of total kidney volume, which is one key relevant, I would say, endpoint to really understand the potential efficacy of a product in this particular condition. Sorry. We are aiming to enroll patients that are rapid progressors, that are defined as rapid progressors based on certain categories, and that will allow us to really see the magnitude of effect in much more shorter period of time.

David AnguloCEO

The design is not so different to what is typically evaluated and seen in this particular type of studies. We will be happy to disclose soon what are the doses that we're going to be integrating into that particular study.

Vamil DivanManaging Director

Maybe just on that total kidney volume- Sorry measures, or what would you be hoping to see when you look at sort of the interim data next year?

David AnguloCEO

Sure. Really the best benchmark information that we have about how TKV evolves when you do have an effective therapy on board is really the data that exists for the current product that is approved, which is tolvaptan, because it's the only product that has been evaluated in a long term that has shown efficacy. What has been observed is that patients not receiving therapy, let's say patients receiving placebo over a year period of time, they typically have a progression of their total kidney volume of about 5%. That subgroup of patients that are typically enrolled in these studies, about 5% increase in total kidney volume in a year. Tolvaptan showed that it was able to reduce that 5% by half, so it had a 50% relative reduction.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day